...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: More Exempt Distribution Investments

Distribution dates stated incorrectly Jan 11, 2023. Should be Jan 11, 2024. ??

A combination of a Promissory Note and Common Shares and Warrants.

Total $545,550.00 (CAN)

Out of Alberta, Manitoba, USA, Quebec, Hong Kong and the British Virgin Islands.

 

Koo

Share
New Message
Please login to post a reply